MYRIAD GENETICS INC FILES (8-K) Disclosing Other Events

ITEM 8.01 Other Events.

On April 1, 2022, Myriad Genetics, Inc. (the "Company") settled the qui tam
lawsuit that was filed by STF, LLC ("Relator") against Crescendo Bioscience, LLC
(formerly known as Crescendo Bioscience, Inc.), a wholly owned subsidiary of the
Company ("Crescendo" and together with the Company, the "Defendants"), and the
Company, which is currently pending in the United States District Court for the
Northern District of California. The Relator filed the qui tam lawsuit in April
2016 alleging claims concerning Crescendo's former test, Vectra, and conduct
dating back to 2010, under the federal False Claims Act, the California False
Claims Act, and the California Insurance Fraud Protection Act (the "CIFPA").
After conducting an investigation of the allegations, in January 2020, the
United States Department of Justice declined to intervene in the lawsuit. Also,
in January 2020, the State of California declined to intervene.

Pursuant to the terms of the settlement agreements, the Company has agreed to
pay a total of $45.25 million to the United States and the State of California
and $2.75 million to Relator's counsel. The Relator has agreed to the dismissal
of the lawsuit with prejudice as to the Relator and fully releases all claims
against the Defendants and their affiliates, directors, officers, and employees.
The State of California has agreed to the dismissal of the lawsuit with
prejudice as to the State of California and releases the Defendants from any
claims submitted to the State's Medicaid program or under the CIFPA as a result
of certain alleged conduct. The United States Department of Justice has approved
the settlement of federal claims, including dismissal of the lawsuit without
prejudice as to the United States.

The settlement agreements contain no admission of liability, wrongdoing or
responsibility on the part of the Defendants. The Company expressly denies any
and all liability for claims alleged in the lawsuit.

--------------------------------------------------------------------------------